Insider · CIK 0001873392
Nathan J Dowden
coopresidentofficer
Files at TRDA (Entrada Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | TRDA Entrada Therapeutics, Inc. | FTax withholding Common Stock | -2,528 | $7.14 | $18k | 196,060 | 39 d ago |
| Sep 2, 2025 | TRDA Entrada Therapeutics, Inc. | FTax withholding Common Stock | -1,746 | $5.43 | $9,481 | 179,059 | Sep 4, 2025 |
| Mar 1, 2025 | TRDA Entrada Therapeutics, Inc. | AGrant or award Common Stock | +60,800 | $0.00 | $0 | 185,949 | Mar 4, 2025 |
| Mar 3, 2025 | TRDA Entrada Therapeutics, Inc. | FTax withholding Common Stock | -5,144 | $11.68 | $60k | 180,805 | Mar 4, 2025 |
| Mar 1, 2025 | TRDA Entrada Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +90,800 | $0.00 | $0 | 90,800 | Mar 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.